MX366405B - Uso de peptidos glp-1 de accion prolongada. - Google Patents

Uso de peptidos glp-1 de accion prolongada.

Info

Publication number
MX366405B
MX366405B MX2014014946A MX2014014946A MX366405B MX 366405 B MX366405 B MX 366405B MX 2014014946 A MX2014014946 A MX 2014014946A MX 2014014946 A MX2014014946 A MX 2014014946A MX 366405 B MX366405 B MX 366405B
Authority
MX
Mexico
Prior art keywords
peptides
long
acting glp
glp
acting
Prior art date
Application number
MX2014014946A
Other languages
English (en)
Other versions
MX2014014946A (es
Inventor
Bjørn Jensen Christine
Frederik Rasmussen Mads
Zdravkovic Milan
Kristensen Peter
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2014014946A publication Critical patent/MX2014014946A/es
Publication of MX366405B publication Critical patent/MX366405B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a uso de péptidos GLP-1 de acción prolongada en ciertos regímenes de dosificación para el tratamiento de diabetes tipo 2, obesidad, etc.
MX2014014946A 2012-07-01 2013-06-21 Uso de peptidos glp-1 de accion prolongada. MX366405B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12174535 2012-07-01
US201261694837P 2012-08-30 2012-08-30
US201261708162P 2012-10-01 2012-10-01
EP12186781 2012-10-01
PCT/EP2013/063004 WO2014005858A1 (en) 2012-07-01 2013-06-21 Use of long-acting glp-1 peptides

Publications (2)

Publication Number Publication Date
MX2014014946A MX2014014946A (es) 2015-04-08
MX366405B true MX366405B (es) 2019-07-08

Family

ID=65858459

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2019008148A MX376058B (es) 2012-07-01 2013-06-21 Uso de peptidos glp-1 de accion prolongada.
MX2014014946A MX366405B (es) 2012-07-01 2013-06-21 Uso de peptidos glp-1 de accion prolongada.
MX2020010693A MX2020010693A (es) 2012-07-01 2014-12-05 Uso de peptidos glp-1 de accion prolongada.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019008148A MX376058B (es) 2012-07-01 2013-06-21 Uso de peptidos glp-1 de accion prolongada.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020010693A MX2020010693A (es) 2012-07-01 2014-12-05 Uso de peptidos glp-1 de accion prolongada.

Country Status (17)

Country Link
US (2) US9764003B2 (es)
EP (3) EP3689365B1 (es)
JP (1) JP6059802B2 (es)
AU (3) AU2013286177B2 (es)
BR (1) BR112014032938A2 (es)
CA (1) CA2877056A1 (es)
DK (1) DK2866825T3 (es)
ES (2) ES3041720T3 (es)
HR (2) HRP20251088T1 (es)
HU (2) HUE049152T2 (es)
MX (3) MX376058B (es)
PL (2) PL3689365T3 (es)
PT (1) PT2866825T (es)
RS (2) RS60432B1 (es)
RU (2) RU2018117557A (es)
SI (1) SI2866825T1 (es)
WO (1) WO2014005858A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
CN106117343B (zh) 2011-04-12 2020-11-03 诺沃—诺迪斯克有限公司 双酰化glp-1衍生物
CA2868188A1 (en) 2012-03-22 2013-09-26 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
CN104487056A (zh) 2012-06-20 2015-04-01 诺和诺德A/S（股份有限公司） 包含肽和递送剂的片剂制剂
RS60432B1 (sr) 2012-07-01 2020-07-31 Novo Nordisk As Upotreba glp-1 peptida sa dugim dejstvom
AU2014261336B2 (en) 2013-05-02 2019-02-28 Novo Nordisk A/S Oral dosing of GLP-1 compounds
KR102321242B1 (ko) * 2014-10-16 2021-11-02 얀마 파워 테크놀로지 가부시키가이샤 작업 차량
GB201621987D0 (en) * 2016-12-22 2017-02-08 Archer Virgil L See Archer Sheri A Arecor Ltd Novel composition
DE102017106216A1 (de) * 2017-03-22 2018-09-27 Amw Gmbh Extrudierte Depotform zur anhaltenden Wirkstofffreisetzung
KR102665710B1 (ko) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도
MY204827A (en) * 2017-10-12 2024-09-18 Novo Nordisk As Semaglutide in medical therapy
GB201720187D0 (en) * 2017-12-04 2018-01-17 Imperial Innovations Ltd Novel Compounds
KR102647171B1 (ko) 2018-02-02 2024-03-15 노보 노르디스크 에이/에스 Glp-1 작용제 및 n-(8-(2-하이드록시벤조일)아미노)카프릴산의 염을 포함하는 고형 조성물
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
WO2020028907A1 (en) * 2018-08-03 2020-02-06 Brown University Compositions and methods for improving the bioavailability of glp1 and analogues thereof
KR20210143766A (ko) * 2019-02-26 2021-11-29 트위스트 바이오사이언스 코포레이션 Glp1 수용체에 대한 변이체 핵산 라이브러리
EP3930757A1 (en) 2019-03-01 2022-01-05 President And Fellows Of Harvard College Methods and compositions for protein delivery
PL4054620T3 (pl) * 2019-11-06 2024-10-14 Novo Nordisk A/S Semaglutyd w leczeniu demencji alzheimera
JP2023510218A (ja) * 2019-12-30 2023-03-13 ガン アンド リー ファーマスゥーティカルズ カンパニー リミテッド 長時間作用型ｇｌｐ－１化合物
JP7761567B2 (ja) * 2020-02-18 2025-10-28 ノヴォ ノルディスク アー／エス 医薬製剤
CN112768087A (zh) * 2020-12-23 2021-05-07 吉林大学 利用孟德尔随机化方法验证索马鲁肽口服制剂预防二型糖尿病的用途
EP4359074A4 (en) * 2021-06-24 2025-06-04 Gila Therapeutics, Inc. METHODS AND KITS FOR INDUCTING SATOURAGE AND TREATMENT OF METABOLIC DISEASES
US12514908B2 (en) 2021-07-05 2026-01-06 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
US11865213B2 (en) * 2021-07-05 2024-01-09 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
PL4408840T3 (pl) 2021-09-27 2025-12-22 Terns Pharmaceuticals, Inc. Kwasy benzoimidazolokarboksylowe jako agoniści glp-1r
WO2023076237A1 (en) 2021-10-25 2023-05-04 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
MX2024005705A (es) 2021-11-10 2024-05-24 I2O Therapeutics Inc Composiciones de liquidos ionicos.
CN115850438B (zh) * 2021-12-28 2023-05-12 北京惠之衡生物科技有限公司 一种长效glp-1衍生物
PE20250741A1 (es) 2022-02-23 2025-03-13 Terns Pharmaceuticals Inc Compuestos como agonistas de glp-1r
WO2023225370A1 (en) * 2022-05-19 2023-11-23 Vault Bioventures, Inc. Obesity treatment and prevention methods
KR20250141711A (ko) 2022-12-30 2025-09-29 알지파마 에이에스 경구 투여되는 폴리펩타이드 치료제의 전신 생체이용률을 증가시키는 조성물 및 방법
KR20250166323A (ko) 2023-04-07 2025-11-27 테른스 파마슈티칼스, 인크. 간 장애 또는 심장대사 질환의 치료에 사용하기 위한 thr베타 효현제 및 glp-1r 효현제를 포함하는 조합
WO2025024455A1 (en) 2023-07-24 2025-01-30 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for delivery of therapeutic peptides
WO2025165146A1 (ko) * 2024-01-29 2025-08-07 주식회사 티온랩테라퓨틱스 세마글루타이드 또는 티르제파타이드의 개선된 의료 요법 제공을 위한 비만 및 당뇨 치료용으로써, 소수성 이온 페어링 겔레이션을 통한 초기 방출이 제어된 데포 조성물 및 이의 제조방법
CN118845644B (zh) * 2024-09-27 2025-01-17 杭州信海医药科技有限公司 一种司美格鲁肽注射液的制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
BRPI9711437B8 (pt) 1996-08-30 2021-05-25 Novo Nordisk As derivados de glp-1
AU2002316811A1 (en) 2001-06-28 2003-03-03 Novo Nordisk A/S Stable formulation of modified glp-1
TW200526254A (en) 2003-09-19 2005-08-16 Novo Nordisk As Novel GLP-1 derivatives
HUE043210T2 (hu) 2003-11-20 2019-08-28 Novo Nordisk As Injekciós eszközök elõállítására optimális propilénglikol-tartalmú peptidkészítmények
CN102772787A (zh) * 2004-11-12 2012-11-14 诺和诺德公司 促胰岛素肽的稳定制剂
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
WO2007121411A2 (en) * 2006-04-14 2007-10-25 Mannkind Corporation Glucagon-like peptide 1(glp-1) pharmaceutical formulations
EP2121897A4 (en) 2007-03-20 2010-03-31 Nippon Kayaku Kk METHOD FOR MONITORING THE DRUG EFFECT ON DIABETES PATIENTS USING AN ASSAY FOR 1,5-ANHYDRO-D-GLUCITOL
WO2008145728A1 (en) 2007-06-01 2008-12-04 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
WO2009030738A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
WO2009030774A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
ES2620610T3 (es) 2008-12-10 2017-06-29 Glaxosmithkline Llc Composiciones farmacéuticas de albiglutide
JP2012517977A (ja) 2009-02-13 2012-08-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害剤（リナグリプチン）を任意で他の抗糖尿病薬と組み合わせて含む抗糖尿病薬
AU2010338387B2 (en) 2009-12-16 2014-10-23 Novo Nordisk A/S Double-acylated GLP-1 derivatives
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
WO2012016419A1 (zh) 2010-08-06 2012-02-09 浙江贝达药业有限公司 Glp-1衍生物及其应用
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN102718858B (zh) 2011-03-29 2014-07-02 天津药物研究院 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
CN102229668A (zh) 2011-06-03 2011-11-02 浙江贝达药业有限公司 一种glp-1衍生物及其应用
JP2014520159A (ja) * 2011-06-24 2014-08-21 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー Ｇｌｐ−１受容体アゴニストの徐放性製剤による糖尿病の治療方法
RS60432B1 (sr) 2012-07-01 2020-07-31 Novo Nordisk As Upotreba glp-1 peptida sa dugim dejstvom

Also Published As

Publication number Publication date
PL3689365T3 (pl) 2025-11-12
HUE049152T2 (hu) 2020-09-28
US9764003B2 (en) 2017-09-19
MX2020010693A (es) 2020-11-06
RU2657573C2 (ru) 2018-06-14
AU2018202504A1 (en) 2018-05-10
WO2014005858A1 (en) 2014-01-09
ES3041720T3 (en) 2025-11-14
EP3689365C0 (en) 2025-08-06
RU2018117557A3 (es) 2021-08-20
HRP20251088T1 (hr) 2025-11-07
EP4406593A3 (en) 2024-10-23
DK2866825T3 (da) 2020-06-08
JP2015522573A (ja) 2015-08-06
AU2020202573A1 (en) 2020-05-07
PL2866825T3 (pl) 2021-02-22
BR112014032938A2 (pt) 2017-08-01
HRP20200889T1 (hr) 2020-09-04
MX2019008148A (es) 2019-09-05
RU2015101826A (ru) 2016-08-20
EP2866825B1 (en) 2020-04-08
JP6059802B2 (ja) 2017-01-11
EP3689365A1 (en) 2020-08-05
AU2013286177A1 (en) 2015-01-15
US20150190474A1 (en) 2015-07-09
EP2866825A1 (en) 2015-05-06
AU2018202504B2 (en) 2020-05-07
US20180085435A1 (en) 2018-03-29
RS67258B1 (sr) 2025-10-31
CA2877056A1 (en) 2014-01-09
EP4406593A2 (en) 2024-07-31
AU2013286177B2 (en) 2018-04-26
RU2018117557A (ru) 2019-03-22
MX2014014946A (es) 2015-04-08
MX376058B (es) 2025-03-07
RS60432B1 (sr) 2020-07-31
US10335462B2 (en) 2019-07-02
SI2866825T1 (sl) 2020-07-31
EP3689365B1 (en) 2025-08-06
ES2796839T3 (es) 2020-11-30
PT2866825T (pt) 2020-07-15
AU2020202573B2 (en) 2023-04-20
HUE072859T2 (hu) 2025-12-28

Similar Documents

Publication Publication Date Title
MX366405B (es) Uso de peptidos glp-1 de accion prolongada.
CL2021000008A1 (es) Uso de un heparinoide para el tratamiento del cáncer (divisional de la solicitud n° 201403017)
CY1121225T1 (el) Συμπυκνωμενες iμιδαζολυλιμιδαζολες ως αντιiκες ενωσεις
CY1120730T1 (el) Απο του στοματος χορηγουμενη δοσολογια ενωσεων glp-1
EA201490070A1 (ru) Коантагонисты глюкагонового рецептора/glp-1-рецептора
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
UA118558C2 (uk) Пептидна сполука
MX2013015168A (es) Co-agonista del receptor de glucagon/glp-1.
DK2728002T3 (da) Heterodimeriseret polypeptid
CL2015001699A1 (es) Compuestos derivados de nucleosidos, nucleotidos y analogos de los mismos; composicion farmaceutica; y su uso para preparar un medicamento util en el tratamiento de la hepatitis c.
EA201690780A1 (ru) Пегилированные лекарственные средства-линкеры для улучшенной фармакокинетики конъюгатов лиганд-лекарственное средство
CL2013002001A1 (es) Uso de un agonista del receptor tipo toll para el tratamiento del cancer.
DK2940135T3 (da) Heterodimeriseret polypeptid
MX2016007063A (es) Peptidos terapeuticos.
JOP20200175A1 (ar) حقنة
CL2015001731A1 (es) Compuestos inhibidores de autotaxina; composicion y combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como fibrosis, prurito, cancer, entre otras.
UY34859A (es) Análogos peptídicos de la exendina 4.
PE20151239A1 (es) Derivados de exendina-4 funcionalizada
CL2014002556A1 (es) Compuestos derivados de ácidos indaniloxidihidrobenzofuranilacéticos, agonistas del receptor gpr40; composiicon farmaceutica; y su uso en el tratamiento de enfermedades o afecciones como diabetes, resistencia a la insulina, obesidad, entre otras.
CL2014001705A1 (es) Compuestos derivados de aza adamantano, inhibidores de 11beta-hsd-1; composicion farmaceutica; metodo para prevencion o tratamiento; y uso para prevenir o tratar el sindrome metabolico, diabetes tipo 2 como consecuencia de obesidad, resisitencia a insulina, dislipidemia, neuropatia, isquemia e infarto, entre otras enfermedades.
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.
BR112015006692A2 (pt) formulação de nanodispersão, método para administrar uma formulação de nanodispersão líquida de taxina livre de etanol em um indivíduo, e, kit.
EA201490041A1 (ru) Пластырь, содержащий диклофенак и тиоколхикозид
TR201100150A2 (tr) Suda çözünür dozaj formları
CL2013001445A1 (es) Compuestos derivados de difenilamina; composicion farmaceutica y uso en el tratamiento de enfermedades inflamatorias, tales como cancer.

Legal Events

Date Code Title Description
FG Grant or registration